{
    "clinical_study": {
        "@rank": "146179", 
        "arm_group": [
            {
                "arm_group_label": "4 mg OTO-201", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "12 mg OTO-201", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Vehicle for OTO-201", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Sham", 
                "arm_group_type": "Sham Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to describe the safety and tolerability of two dose levels of\n      OTO-201, placebo and sham when administered intra-operatively in pediatric subjects with\n      bilateral middle ear effusion who require tympanostomy tube placement."
        }, 
        "brief_title": "OTO-201 for Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Bilateral Middle Ear Effusion Requiring Tympanostomy Tube Placement", 
        "condition_browse": {
            "mesh_term": "Otitis Media with Effusion"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria includes, but is not limited to:\n\n          -  Subject is a male or female aged 6 months to 12 years, inclusive\n\n          -  Subject has a clinical diagnosis of bilateral middle ear effusion requiring\n             tympanostomy tube placement\n\n          -  Subject's caregiver is willing to comply with the protocol and attend all study\n             visits\n\n        Exclusion Criteria includes, but is not limited to:\n\n          -  Subject has a history of prior ear or mastoid surgery, not including myringotomy or\n             myringotomy with tympanostomy tube placement\n\n          -  Subject has a history of sensorineural hearing loss\n\n          -  Subject has a history of chronic or recurrent bacterial infections other than otitis\n             media that likely will require treatment with antibiotics during the course of the\n             study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "12 Years", 
            "minimum_age": "6 Months"
        }, 
        "enrollment": {
            "#text": "83", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01755286", 
            "org_study_id": "201-201101"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "4 mg OTO-201", 
                    "12 mg OTO-201"
                ], 
                "description": "Single intra-operative injection", 
                "intervention_name": "OTO-201", 
                "intervention_type": "Drug", 
                "other_name": "ciprofloxacin"
            }, 
            {
                "arm_group_label": "Vehicle for OTO-201", 
                "description": "Single intratympanic injection", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sham", 
                "description": "Simulated single intratympanic injection", 
                "intervention_name": "Sham", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ciprofloxacin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 17, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Diego", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92121"
                }, 
                "name": "Call/Email Otonomy Central Contact for Trial Locations"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Prospective, Randomized, Double-Blind, Placebo- and Sham-Controlled, Multicenter, Phase 1b Study of OTO-201 Given as a Single Intratympanic Injection for Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement", 
        "overall_official": {
            "affiliation": "Otonomy, Inc.", 
            "last_name": "Carl LeBel, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Evaluation of adverse events, otoscopic exams, audiometry, and tympanometry", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 1 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01755286"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Evaluation of physician reported and caregiver reported otorrhea", 
                "measure": "Clinical Activity", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 month"
            }, 
            {
                "description": "Microbiological eradication of pretherapy bacteria", 
                "measure": "Microbiological Eradication", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 month"
            }
        ], 
        "source": "Otonomy, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Otonomy, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}